FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094686032> ?p ?o ?g. }

• W3094686032 endingPage "26" @default.
• W3094686032 startingPage "26" @default.
• W3094686032 abstract "Background: Humoral and cell-mediated immune dysregulation is a hallmark of chronic lymphocytic leukemia (CLL) and predisposes these patients to recurrent infections, which remain the leading cause of mortality. Ibrutinib is widely used in both treatment-naive and relapsed CLL, and these patientshave a 48% cumulative rate of ≥grade 3 infections over a 5-year follow up (O'Brien et al.; Blood, April 2018). Our study evaluated humoral immunity in patients with CLL treated with ibrutinib by checking immunoglobulin (Ig) levels and vaccine responses. Methods: We measured serum IgG, IgM, IgA, and pre/post-vaccine IgG titers to diphtheria, tetanus, and Streptococcus pneumoniae in patients with CLL on treatment with ibrutinib. Patients were vaccinated with tetanus/diphtheria (Td) and the pneumococcal polysaccharide (PPV23) vaccines, with post-vaccination titers measured at four weeks. Descriptive statistics are reported with medians and interquartile ranges (IQR). Response to Td was defined as a two-fold increase in specific IgG into the protective range. Response to PPV23 was defined as a two-fold increase from baseline if pre-vaccination specific IgG ≥1.3 microgram per milliliter (mcg/ml), or if titers increased by four-fold from baseline if pre-vaccination specific IgG &lt; 1.3 mcg/ml, for &gt; 70% of the serotypes. Results: Ten patients were enrolled. The median age was 65 (IQR: 60-68) years; seven were male. The median time since diagnosis was 4.7 (IQR: 4-9.1) years. Patients were on ibrutinib for a median time of 1.3 (IQR: 0.4-2.8) years at the time of enrollment. Three patients had previously received treatment with rituximab monotherapy, while two patients had received prior combination therapy with fludarabine-rituximab-lenalidomide and fludarabine-cyclophosphamide-rituximab. Nine patients had received at least one course of antibiotics (ABx) in the year before enrollment; the median number of ABx courses was 2 (IQR 2-3). Four patients were on prophylactic antibiotics, and three had previously received immunoglobulin replacement therapy. The median serum IgG titer was 650 (IQR: 544-820) mg/dl. 40% (4/10) of patients responded to vaccination with diphtheria, 30% (3/10) of patients responded to vaccination with tetanus, and none of the patients responded to PPV23 (see Table 1). Conclusion: Patients with CLL treated with ibrutinib demonstrate a high prevalence of humoral dysfunction, as evidenced by suboptimal vaccine responses to both peptide and polysaccharide antigens despite adequate Ig levels. Clinicians should consider checking vaccine responses in conjunction with Ig levels for comprehensive evaluation of humoral dysfunction. Disclosures Mustafa: Genentech: Speakers Bureau; AstraZeneca: Speakers Bureau; Regeneron: Speakers Bureau; CSL Behring: Speakers Bureau. Jamshed:Takeda, Amgen and Celgene: Honoraria." @default.
• W3094686032 created "2020-11-09" @default.
• W3094686032 creator A5023548389 @default.
• W3094686032 creator A5051605988 @default.
• W3094686032 creator A5057177519 @default.
• W3094686032 creator A5080239879 @default.
• W3094686032 date "2020-11-05" @default.
• W3094686032 modified "2023-09-27" @default.
• W3094686032 title "Humoral Dysfunction in Patients with Chronic Lymphocytic Leukemia on Ibrutinib As Evidenced By Suboptimal Vaccine Responses" @default.
• W3094686032 doi "https://doi.org/10.1182/blood-2020-142731" @default.
• W3094686032 hasPublicationYear "2020" @default.
• W3094686032 type Work @default.
• W3094686032 sameAs 3094686032 @default.
• W3094686032 citedByCount "0" @default.
• W3094686032 crossrefType "journal-article" @default.
• W3094686032 hasAuthorship W3094686032A5023548389 @default.
• W3094686032 hasAuthorship W3094686032A5051605988 @default.
• W3094686032 hasAuthorship W3094686032A5057177519 @default.
• W3094686032 hasAuthorship W3094686032A5080239879 @default.
• W3094686032 hasBestOaLocation W30946860321 @default.
• W3094686032 hasConcept C119060515 @default.
• W3094686032 hasConcept C126322002 @default.
• W3094686032 hasConcept C159654299 @default.
• W3094686032 hasConcept C203014093 @default.
• W3094686032 hasConcept C22070199 @default.
• W3094686032 hasConcept C2777938653 @default.
• W3094686032 hasConcept C2778461978 @default.
• W3094686032 hasConcept C2779664119 @default.
• W3094686032 hasConcept C2779878957 @default.
• W3094686032 hasConcept C2780572238 @default.
• W3094686032 hasConcept C2780898057 @default.
• W3094686032 hasConcept C2781253189 @default.
• W3094686032 hasConcept C3020803494 @default.
• W3094686032 hasConcept C32611913 @default.
• W3094686032 hasConcept C523546767 @default.
• W3094686032 hasConcept C54355233 @default.
• W3094686032 hasConcept C71924100 @default.
• W3094686032 hasConcept C86803240 @default.
• W3094686032 hasConceptScore W3094686032C119060515 @default.
• W3094686032 hasConceptScore W3094686032C126322002 @default.
• W3094686032 hasConceptScore W3094686032C159654299 @default.
• W3094686032 hasConceptScore W3094686032C203014093 @default.
• W3094686032 hasConceptScore W3094686032C22070199 @default.
• W3094686032 hasConceptScore W3094686032C2777938653 @default.
• W3094686032 hasConceptScore W3094686032C2778461978 @default.
• W3094686032 hasConceptScore W3094686032C2779664119 @default.
• W3094686032 hasConceptScore W3094686032C2779878957 @default.
• W3094686032 hasConceptScore W3094686032C2780572238 @default.
• W3094686032 hasConceptScore W3094686032C2780898057 @default.
• W3094686032 hasConceptScore W3094686032C2781253189 @default.
• W3094686032 hasConceptScore W3094686032C3020803494 @default.
• W3094686032 hasConceptScore W3094686032C32611913 @default.
• W3094686032 hasConceptScore W3094686032C523546767 @default.
• W3094686032 hasConceptScore W3094686032C54355233 @default.
• W3094686032 hasConceptScore W3094686032C71924100 @default.
• W3094686032 hasConceptScore W3094686032C86803240 @default.
• W3094686032 hasIssue "Supplement 1" @default.
• W3094686032 hasLocation W30946860321 @default.
• W3094686032 hasOpenAccess W3094686032 @default.
• W3094686032 hasPrimaryLocation W30946860321 @default.
• W3094686032 hasRelatedWork W1506121387 @default.
• W3094686032 hasRelatedWork W2012165192 @default.
• W3094686032 hasRelatedWork W2030318309 @default.
• W3094686032 hasRelatedWork W2065867292 @default.
• W3094686032 hasRelatedWork W2075208494 @default.
• W3094686032 hasRelatedWork W2123520510 @default.
• W3094686032 hasRelatedWork W2127989327 @default.
• W3094686032 hasRelatedWork W2151488936 @default.
• W3094686032 hasRelatedWork W2316189750 @default.
• W3094686032 hasRelatedWork W2606614071 @default.
• W3094686032 hasVolume "136" @default.
• W3094686032 isParatext "false" @default.
• W3094686032 isRetracted "false" @default.
• W3094686032 magId "3094686032" @default.
• W3094686032 workType "article" @default.